What is Chediak Higashi Syndrome

Chediak-Higashi syndrome is a rare, inherited immune disorder characterized by impaired function of white blood cells, resulting in recurrent infections, partial albinism, and neurological issues. It is caused by mutations in the LYST gene, which disrupts the normal structure and function of lysosomes within cells.

What are the primary symptoms of Chediak-Higashi syndrome?

Because Chediak-Higashi syndrome affects the way cells transport proteins, it impacts multiple body systems. The most common clinical features include:

• Immune deficiency: Frequent, severe bacterial and viral infections due to white blood cells failing to destroy pathogens.


• Oculocutaneous albinism: Lighter skin, hair, and eye color than family members, often accompanied by sensitivity to light (photophobia).


• Neurological involvement: Progressive weakness, sensory deficits, and cognitive challenges that may develop over time.


• Bleeding issues: A tendency to bruise or bleed easily due to abnormal platelet function.

How common is Chediak-Higashi syndrome?

Chediak-Higashi syndrome is extremely rare, with fewer than 500 cases reported in medical literature worldwide. It is an autosomal recessive condition, meaning a child must inherit two copies of the mutated gene—one from each parent—to develop the disorder. While it can affect any gender or ethnic group, it is most often diagnosed in early childhood.

What causes Chediak-Higashi syndrome?

The underlying mechanism of Chediak-Higashi syndrome involves mutations in the LYST gene. This gene provides instructions for creating a protein that regulates the size and function of lysosomes, which are the "recycling centers" of the cell. In Chediak-Higashi syndrome, these lysosomes become abnormally large, preventing cells like neutrophils and melanocytes from functioning correctly.

How is this different from other immune disorders?

What differentiates Chediak-Higashi syndrome from other primary immunodeficiencies is the combination of immune dysfunction and distinct pigmentary changes. Additionally, many patients may eventually enter an "accelerated phase," characterized by an aggressive, lymphoma-like infiltration of organs by immune cells, which requires specialized medical intervention.

Next steps

• Consult with a clinical geneticist or pediatric immunologist to discuss testing and specialized care.


• Connect with the DiseaseMaps.org community to share experiences with others living with this rare condition.


• Monitor for signs of the accelerated phase, such as persistent fevers or unexplained bruising, and seek immediate specialized care.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Chediak-Higashi syndrome overview.


• Orphanet: Rare disease database entry for Chediak-Higashi syndrome (ORPHA:167).


• OMIM (Online Mendelian Inheritance in Man): Entry #214500.


• Primary Immune Deficiency Treatment Consortium (PIDTC) clinical guidelines.